The rationale behind a vaccine based on multiple HIV antigens

被引：32

作者：

Rollman, E

Bråve, A

Boberg, A

Gudmundsdotter, L

Engström, G

Isaguliants, A

Ljungberg, K

Lundgren, B

Blomberg, P

Hinkula, J

Hejdeman, B

Sandström, E

Liu, M

Wahren, B ^{[1
]}

机构：

[1] Swedish Inst Infect Dis Control, Solna, Sweden

[2] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17182 Stockholm, Sweden

[3] Swedish Inst Infect Dis Control, S-17182 Stockholm, Sweden

[4] Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC USA

[5] Visionar Biomed AB, Uppsala, Sweden

[6] Karolinska Univ Hosp, Vecura, Stockholm, Sweden

[7] Karolinska Univ Hosp, Sodersjukhuset, Venhalsan, Stockholm, Sweden

[8] Transgene SA, Strasbourg, France

来源：

MICROBES AND INFECTION | 2005年 / 7卷 / 14期

关键词：

HIV-1; DNA vaccine; clinical trials;

D O I：

10.1016/j.micinf.2005.07.017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials. (c) 2005 Elsevier SAS. All rights reserved.

引用

收藏

页码：1414 / 1423

页数：10

相关论文

共 43 条

[1]

*5 FWP 5 FRAM PROG, STUD IMM DNA HIV 1 E

[2] HIV-1 superinfection [J].

Allen, TM ;

Altfeld, M .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 112 (05) :829-835

[3] Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor [J].

Armitage, JO .

BLOOD, 1998, 92 (12) :4491-4508

[4]

ARTEGA H, 2003, THESIS KAROLINSKA I

[5] The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania:: a potential population for HIV vaccine trials [J].

Bakari, M ;

Lyamuya, E ;

Mugusi, F ;

Aris, E ;

Chale, S ;

Magao, P ;

Jossiah, R ;

Janabi, M ;

Swai, A ;

Pallangyo, N ;

Sandström, E ;

Mhalu, F ;

Biberfeld, G ;

Pallangyo, K .

AIDS, 2000, 14 (03) :313-320

[6] Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF [J].

Barouch, DH ;

Santra, S ;

Tenner-Racz, K ;

Racz, P ;

Kuroda, MJ ;

Schmitz, JE ;

Jackson, SS ;

Lifton, MA ;

Freed, DC ;

Perry, HC ;

Davies, ME ;

Shiver, JW ;

Letvin, NL .

JOURNAL OF IMMUNOLOGY, 2002, 168 (02) :562-568

[7] HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 CHALLENGE OF CHIMPANZEES IMMUNIZED WITH RECOMBINANT ENVELOPE GLYCOPROTEIN GP120 [J].

BERMAN, PW ;

GROOPMAN, JE ;

GREGORY, T ;

CLAPHAM, PR ;

WEISS, RA ;

FERRIANI, R ;

RIDDLE, L ;

SHIMASAKI, C ;

LUCAS, C ;

LASKY, LA ;

EICHBERG, JW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) :5200-5204

[8] Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].

Cafaro, A ;

Caputo, A ;

Fracasso, C ;

Maggiorella, MT ;

Goletti, D ;

Baroncelli, S ;

Pace, M ;

Sernicola, L ;

Koanga-Mogtomo, ML ;

Betti, M ;

Borsetti, A ;

Belli, R ;

Åkerblom, L ;

Corrias, F ;

Buttò, S ;

Heeney, J ;

Verani, P ;

Titti, F ;

Ensoli, B .

NATURE MEDICINE, 1999, 5 (06) :643-650

[9] Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].

Calarota, S ;

Bratt, G ;

Nordlund, S ;

Hinkula, J ;

Leandersson, AC ;

Sandström, E ;

Wahren, B .

LANCET, 1998, 351 (9112) :1320-1325

[10] Gene combination raises broad human immunodeficiency virus-specific cytotoxicity [J].

Calarota, SA ;

Kjerrström, A ;

Islam, KB ;

Wahren, B .

HUMAN GENE THERAPY, 2001, 12 (13) :1623-1637

← 1 2 3 4 5 →